Related references
Note: Only part of the references are listed.Roles and mechanisms of BAP1 deubiquitinase in tumor suppression
Louis Masclef et al.
CELL DEATH AND DIFFERENTIATION (2021)
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman et al.
CANCER DISCOVERY (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Systemic therapies for intrahepatic cholangiocarcinoma
Robin Kate Kelley et al.
JOURNAL OF HEPATOLOGY (2020)
Second-line therapies in advanced biliary tract cancers
Sri Harsha Tella et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors
Eunhae Shin et al.
BMC OPHTHALMOLOGY (2020)
FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
Lipika Goyal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young K. Chae et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Molecular targeted therapies: Ready for prime time in biliary tract cancer
Angela Lamarca et al.
JOURNAL OF HEPATOLOGY (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
Jose J. G. Marin et al.
BRITISH JOURNAL OF CANCER (2020)
Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma
Min Zhang et al.
JOURNAL OF HEPATOLOGY (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2020)
Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
Angela Lamarca et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
Ze-Long Liu et al.
FRONTIERS IN MEDICINE (2020)
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options
Nicola Personeni et al.
CANCERS (2020)
Prevention and treatment of FGFR inhibitor-associated toxicities
Amit Mahipal et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
FGFR inhibitors in cholangiocarcinoma: what's now and what's next?
Anna Saborowski et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Martin H. Voss et al.
CLINICAL CANCER RESEARCH (2019)
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Paola Bertuccio et al.
JOURNAL OF HEPATOLOGY (2019)
AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results
Matthew C. H. Ng et al.
HEPATOBILIARY SURGERY AND NUTRITION (2019)
Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Rastislav Bahleda et al.
CLINICAL CANCER RESEARCH (2019)
Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review
Rodolfo Chicas-Sett et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations.
Joon Oh Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.
Yung-Jue Bang et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC plus mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.
Angela Lamarca et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial
Rachna T. Shroff et al.
JAMA ONCOLOGY (2019)
O-005Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial
J Harding et al.
ANNALS OF ONCOLOGY (2019)
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai et al.
CELLS (2019)
Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade
Xiaoliang Liu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Intrahepatic Cholangiocarcinoma
Ramy El-Diwany et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2019)
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro et al.
BRITISH JOURNAL OF CANCER (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy
Melanie A. Krook et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2019)
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients Efficacy and Safety of Combination
Francesco Fiorica et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2018)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas
Julia Delahousse et al.
EUROPEAN JOURNAL OF CANCER (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma
Qian Qin et al.
RADIATION RESEARCH (2018)
Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients
Anissa Roger et al.
ONCOIMMUNOLOGY (2018)
LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance
Daichao Wu et al.
CHEMICAL COMMUNICATIONS (2018)
Novel targeted treatment options for advanced cholangiocarcinoma
Amit Mahipal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting
Brendan Farrell et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2018)
HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Salvatore Galdy et al.
CANCER AND METASTASIS REVIEWS (2017)
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2017)
Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center
Andrew Sharabi et al.
ONCOLOGIST (2017)
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
Michael Michael et al.
TARGETED ONCOLOGY (2017)
New Horizons for Precision Medicine in Biliary Tract Cancers
Juan W. Valle et al.
CANCER DISCOVERY (2017)
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
Jacqueline Fontugne et al.
ONCOTARGET (2017)
Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma
Yun Shin Chun et al.
CANCER CONTROL (2017)
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshad Farshidfar et al.
CELL REPORTS (2017)
Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases
Huaibin Chen et al.
ELIFE (2017)
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Agrin Moeini et al.
CLINICAL CANCER RESEARCH (2016)
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
Faiz Gani et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Liver Transplantation for Very Early Intrahepatic Cholangiocarcinoma: International Retrospective Study Supporting a Prospective Assessment
G. Sapisochin et al.
HEPATOLOGY (2016)
Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise
Supriya K. Saha et al.
ONCOLOGIST (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency
Vitor Werneck Krauss Silva et al.
CHINESE CLINICAL ONCOLOGY (2016)
Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways
Sarinya Kongpetch et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2015)
HER2/neu-directed therapy for biliary tract cancer
Milind Javle et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer (vol 513, 110, 2014)
Supriya K. Saha et al.
NATURE (2015)
Genomic spectra of biliary tract cancer
Hiromi Nakamura et al.
NATURE GENETICS (2015)
Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Daniela Sia et al.
NATURE COMMUNICATIONS (2015)
The Fibroblast Growth Factor signaling pathway
David M. Ornitz et al.
WILEY INTERDISCIPLINARY REVIEWS-DEVELOPMENTAL BIOLOGY (2015)
Geographic Variation of Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, and Hepatocellular Carcinoma in the United States
Sean F. Altekruse et al.
PLOS ONE (2015)
Very Early'' Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients?
G. Sapisochin et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2014)
Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets
Andrew X. Zhu et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma
Rondell P. Graham et al.
HUMAN PATHOLOGY (2014)
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
John Bridgewater et al.
JOURNAL OF HEPATOLOGY (2014)
FGF Receptors: Cancer Biology and Therapeutics
Masaru Katoh et al.
MEDICINAL RESEARCH REVIEWS (2014)
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Jeffrey S. Ross et al.
ONCOLOGIST (2014)
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Chaitanya R. Churi et al.
PLOS ONE (2014)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao et al.
NATURE GENETICS (2013)
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
P. Wang et al.
ONCOGENE (2013)
Structural Mimicry of A-Loop Tyrosine Phosphorylation by a Pathogenic FGF Receptor 3 Mutation
Zhifeng Huang et al.
STRUCTURE (2013)
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Yi-Mi Wu et al.
CANCER DISCOVERY (2013)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Alternatively Spliced Acid Box Region Plays a Key Role in FGF Receptor Autoinhibition
Juliya Kalinina et al.
STRUCTURE (2012)
Understanding the Impact of the P-loop Conformation on Kinase Selectivity
Cristiano R. W. Guimaraes et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2011)
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
T. Okusaka et al.
BRITISH JOURNAL OF CANCER (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Burden of Digestive Diseases in the United States Part III: Liver, Biliary Tract, and Pancreas
James E. Everhart et al.
GASTROENTEROLOGY (2009)
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases
Huaibin Chen et al.
MOLECULAR CELL (2007)
Structural basis for fibroblast growth factor receptor activation
M Mohammadi et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2005)
Share Paper
